Degradation Of Aggregates Research Articles

The Genetics of Autophagy in Multicellular Organisms.

Autophagy, a lysosome-mediated degradation process evolutionarily conserved from yeast to mammals, is essential for maintaining cellular homeostasis and combating diverse cellular stresses. Autophagy involves de novo synthesis of a double-membrane autophagosome, sequestration of selected cellular contents, and subsequent delivery of sequestrated contents to the vacuole (in yeasts and plants) or to lysosomes (in animal cells) for degradation and recycling. Genetic studies in unicellular and multicellular model organisms have systematically revealed the molecular machinery, regulation, and function of autophagy in physiological settings. I review genetic studies in model organisms-from yeast to worm to fly-that enable us to not only identify autophagy genes, including ATG genes and the metazoan-specific EPG genes, but also uncover variants of autophagy in developmental contexts, novel regulatory mechanisms, and signaling events involved in mediating systemic autophagy response. Genetic analysis also helps us understand the liquid-liquid phase separation and transition that control autophagic degradation of protein aggregates. The emerging role of autophagy in zebrafish tissue regeneration is also discussed.

The Regulation of Basal Autophagic Flux by an ATG13‐ATG101 Complex

Autophagy is an essential cellular process by which cellular debris is collected and broken down in the lysosome. Cancer cells rely on autophagy for survival during chemotherapy treatment and periods of hypoxia within solid tumors. In this project, we investigate the ATG13‐ATG101 protein complex, a sub‐complex of the ULK1 initiatory complex whose regulatory role in autophagy is not completely understood. Our recent data demonstrate that an ULK1‐independent ATG13‐ATG101 complex is essential for the basal autophagic degradation of protein aggregates—a process known as aggrephagy. Furthermore, we found that the ULK1‐independent ATG13‐ATG101 complex traffics to condensates of poly‐ubiquitinated protein aggregates where it colocalizes with the autophagy regulator ATG9A.1 Our current data suggest that this ATG13‐ATG101 complex cooperates with ATG9A in the degradation of these protein aggregates. To further elucidate the function of the ATG13‐ATG101 complex, we have developed a protein‐fragment complementation assay using a novel split TurboID (BioID) system in which complementary halves of TurboID are fused to ATG13 and ATG101. Using this split BioID system, together with quantitative LC‐MS/MS and mutants of ATG13 that cannot bind ULK1, we are identifying interactors that are unique to the ULK1‐independent ATG13‐ATG101 complex. Based on previous data, we hypothesize that the ATG13‐ATG101 sub‐complex participates in ATG9A trafficking pathways and recruitment of autophagy regulators to protein aggregate condensates. Thus, our project characterizes the first proximity interactome for the ATG13‐ATG101 complex.1. Kannangara, A. R.; Poole, D. M.; McEwan, C. M.; Youngs, J. C.; Weerasekara, V. K.; Thornock, A. M.; Lazaro, M. T.; Balasooriya, E. R.; Oh, L. M.; Soderblom, E. J.; Lee, J. J.; Simmons, D. L.; Andersen, J. L., BioID reveals an ATG9A interaction with ATG13‐ATG101 in the degradation of p62/SQSTM1‐ubiquitin clusters. EMBO Rep2021, e51136.

Distribution of phosphorus fractions in soil aggregates in Chinese fir plantations with different stand ages

Exploring the distribution of phosphorus (P) fractionsin soil aggregates is helpful to improve soil P availa-bility during Chinese fir planting. In this study, soil samples were collected in the 0-20 cm soil layer from Chinese fir plantations with different stand ages (9 a, 17 a, and 26 a) and one nearby abandoned land (CK) in Rongshui County, Guangxi, China. Soil aggregates were classified into >2 mm, 1-2 mm, 0.25-1 mm, and <0.25 mm size classes through dry-sieving process, and then soil P fractions in different sized aggregates were measured. These results showed that: 1) The composition of soil aggregates showed significant difference among different stand ages. As the major aggregate fractions in soil, the contents of >2 mm aggregates increased firstly and then decreased over time, and peaked in the 17 a Chinese fir plantation. The changes of soil mean weight diameter (MWD) and geometric mean diameter (GMD) during Chinese fir planting were the same as the content of >2 mm aggregates. 2) Soil total P, inorganic P, and organic P contents did not differ among different sized aggregates. However, soil available P content was mainly distributed in >2 mm aggregates with a range of 1.23-7.33 mg·kg-1. Compared with CK, soil total P, available P, and inorganic P contents were significantly higher in Chinese fir plantations, and their contents increased firstly and then decreased over time. Soil total P (322.40 mg·kg-1) and available P (7.33 mg·kg-1) contents were the highest in the 9 a plantations, and soil inorganic P content (114.05 mg·kg-1) was the highest in the 17 a plantation. Moreover, soil organic P content showed an order of 9 a > 26 a >17 a > CK, with the highest content (210.00 mg·kg-1) in the 9 a plantation. 3) The distribution of P stock in soil aggregates was related to the contents of different sized aggregates, with >2 mm aggregates having the highest P stock. Except for organic P, soil P stock increased firstly and then decreased with the increases of stand age. In conclusion, Chinese fir planting was helpful to improve soil aggregate stability and to promote the increase of soil P level before the stand age of 17 a. However, Chinese fir planting could result in the degradation of soil aggregates and in the decrease of soil P level after 17 a. The formation and stabilization of >2 mm aggregates played an important role in the maintenance of soil quality and soil P supply level after 17 a Chinese fir planting.

CCT2 is an aggrephagy receptor for clearance of solid protein aggregates

Protein aggregation is a hallmark of multiple human pathologies. Autophagy selectively degrades protein aggregates via aggrephagy. How selectivity is achieved has been elusive. Here, we identify the chaperonin subunit CCT2 as an autophagy receptor regulating the clearance of aggregation-prone proteins in the cell and the mouse brain. CCT2 associates with aggregation-prone proteins independent of cargo ubiquitination and interacts with autophagosome marker ATG8s through a non-classical VLIR motif. In addition, CCT2 regulates aggrephagy independently of the ubiquitin-binding receptors (P62, NBR1, and TAX1BP1) or chaperone-mediated autophagy. Unlike P62, NBR1, and TAX1BP1, which facilitate the clearance of protein condensates with liquidity, CCT2 specifically promotes the autophagic degradation of protein aggregates with little liquidity (solid aggregates). Furthermore, aggregation-prone protein accumulation induces the functional switch of CCT2 from a chaperone subunit to an autophagy receptor by promoting CCT2 monomer formation, which exposes the VLIR to ATG8s interaction and, therefore, enables the autophagic function.

Material properties of phase-separated TFEB condensates regulate the autophagy-lysosome pathway.

Very little is known about how the material properties of protein condensates assembled via liquid-liquid phase separation (LLPS) are maintained and affect physiological functions. Here we show that liquid-like condensates of the transcription factor TFEB exhibit low fusion propensity in vitro and in living cells. We directly measured the attraction force between droplets, and we characterized the interfacial tension, viscosity, and elasticity of TFEB condensates. TFEB condensates contain rigid interfacial boundaries that govern their interaction behaviors. Several small molecules, including Ro-3306, modify the material properties of TFEB condensates, increasing their size and fusion propensity. These compounds promote lysosomal biogenesis and function in a TFEB-dependent manner without changing its cytoplasmic-nuclear translocation. Ro-3306 promotes autophagy activity, facilitating degradation of toxic protein aggregates. Our study helps explain how protein condensates are maintained as physically separate entities and reveals that the material properties of TFEB condensates can be harnessed to modulate TFEB activity.

Decreased soil aggregation and reduced soil organic carbon activity in conventional vegetable fields converted from paddy fields

AbstractSoil structure and organic carbon are key factors that reflect soil quality in sustainable agricultural production. Many studies have concentrated on soil aeration under intensive anthropogenic agricultural practices, but the relationship between soil aggregate stability and soil organic carbon (SOC) functional groups is poorly understood, particularly in degraded greenhouse vegetable fields converted from paddy fields. To solve this problem, soil samples were collected from local vegetable fields and adjacent paddy fields. Conventional open‐air vegetable fields and greenhouse vegetable fields, both with a 6–8‐year cultivation history following conversion from paddy fields, were considered. SOC functional groups were characterised by 13C cross‐polarisation magic‐angle‐spinning nuclear magnetic resonance (13C CPMAS NMR). The results showed that the mean weight diameter (MWD) values of water‐stable soil aggregates in the open‐air vegetable fields and greenhouse vegetable fields decreased by 64.6% and 66.7%, respectively, compared with those in the paddy fields. Similar results were obtained for the soil aggregate distribution, and soil aggregates in the greenhouse vegetable fields and open‐air vegetable fields were mainly in the 0.25–2 mm size classes. Among all SOC functional groups, O‐alkyl C exhibited the greatest decrease after the conversion of paddy fields to vegetable fields, no matter whether greenhouse vegetable fields or open‐air vegetable fields. The degradation of soil structure decreased the physical protection of SOC functional groups by soil aggregates, and therefore, decreased the total SOC content and labile C functional group fractions in bulk soil. At the soil aggregate scale, the decrease of O‐alkyl C mainly occurred in microaggregates (0.053–0.25 mm), while aromatic C decreased significantly in macroaggregates (>0.25 mm) in the greenhouse vegetable fields converted from paddy fields. Correlation analysis showed that O‐alkyl C was significantly positively related to MWD and the proportion of large soil macroaggregate (>2 mm). This result suggested that soil aggregates become fragile in long‐term vegetable cultivation after conversion from paddy fields, and a large loss of O‐alkyl C might be the main reason for this phenomenon.Highlights Soil aggregation was significantly decreased in conventional vegetable fields converted from paddy fields. SOC accumulation was closely positively related to soil macroaggregate formation. O‐alkyl C mainly decreased in microaggregates, with the opposite observed for aromatic C, in soil of greenhouse vegetable fields. The large loss of O‐alkyl C may explain the degradation of soil aggregates.

Evaluation of mechanical degradation characteristics of recycled and natural aggregates under gyratory compaction effort

Due to the reduced availability and increased cost of stiff and durable natural aggregates, the use of recycled aggregates to replace natural aggregates has gained popularity. However, recycled aggregates are prone to carrying a greater potential for mechanical degradation (i.e., breakage or physical abrasion) than natural aggregates due to their compositions and two-phase structures, as they typically contain two different materials in their matrices. Since mechanical degradation of aggregates can adversely affect the long-term performance of pavement systems (stiffness, durability, etc.), using regression models to estimate the mechanical degradation characteristics of aggregates during the material selection process would bring significant benefits to state departments of transportation (DOTs) and local transportation agencies. In this study, the Gyratory Abrasion and Image Analysis (GAIA) method was adopted to evaluate the mechanical degradation characteristics of five different recycled aggregates and one natural aggregate. The index properties, compositions, and morphologies of the aggregates were determined to develop regression models for evaluating such characteristics of the aggregates. Overall, the recycled aggregates exhibited higher (as high as 4.3 times) mechanical degradation than the natural aggregate. The regression models showed that oven-dry (OD) specific gravity (Gs) and median roundness of aggregates can be used to predict the mechanical degradation characteristics of both recycled and natural aggregates.

Dual-targeted magnetic mesoporous silica nanoparticles reduce brain amyloid-β burden via depolymerization and intestinal metabolism.

Rationale: Active removal of excess peripheral amyloid-β (Aβ) can potentially treat Alzheimer's disease (AD). However, the peripheral clearance of Aβ using an anti-Aβ monoclonal antibody (mAb) cannot remove PET-detectable Aβ within the brain. This may be due to the inability of mAb to cross the blood-brain barrier (BBB) to degrade insoluble brain Aβ plaques and block liver dysfunction.Methods: We developed a dual-targeted magnetic mesoporous silica nanoparticle (HA-MMSN-1F12) through surface-coupled Aβ42-targeting antibody 1F12 and CD44-targeting ligand hyaluronic acid (HA).Results: HA-MMSN-1F12 had a high binding affinity toward Aβ42 oligomers (Kd = 1.27 ± 0.34 nM) and revealed robust degradation of Aβ42 aggregates. After intravenous administration of HA-MMSN-1F12 into ten-month-old APP/PS1 mice for three weeks (4 mg/kg/week), HA-MMSN-1F12 could cross the BBB and depolymerize brain Aβ plaques into soluble Aβ species. In addition, it also avoided hepatic uptake and excreted captured Aβ species through intestinal metabolism, thereby reducing brain Aβ load and neuroinflammation and improving memory deficits of APP/PS1 mice. Furthermore, the biochemical analysis showed that HA-MMSN-1F12 did not detect any toxic side effects on the liver and kidney. Thus, the efficacy of HA-MMSN-1F12 is associated with the targeted degradation of insoluble brain Aβ plaques, avoidance of non-specific hepatic uptake, and excretion of peripheral Aβ through intestinal metabolism.Conclusions: The study provides a new avenue for treating brain diseases by excreting disease-causing biohazards using intestinal metabolism.

Degradation of amyloid peptide aggregates by targeted singlet oxygen delivery from a benzothiazole functionalized naphthalene endoperoxide.

Aggregate structures formed by amyloid-β (Aβ) are correlated with the progression of pathogenesis in Alzheimer's disease. Previous works have shown that photodynamic photosensitizers were effective in oxidatively degrading amyloid-β aggregates and thus decreasing their cytotoxicity under various conditions. In this work, we designed and synthesized a benzothiazole-naphthalene conjugate, with high level of structural analogy to Thioflavin T which is known to have high affinities for the amyloid peptide aggregates. The endoperoxide form (BZTN-O2) of this compound, which releases singlet oxygen with a half-life of 77 minutes at 37 °C, successfully inhibited and/or reversed amyloid aggregation. The endoperoxide is capable of singlet oxygen release without any need for light, and its charge-neutral form could allow blood-brain barrier (BBB) permeability. The therapeutic potential of such endoperoxide compounds with amyloid binding affinity is exciting.

Mechanisms of autophagy regulation by adiponectin

Adiponectin is a multifunctional adipocytokine produced predominantly by adipocytes, with potent antiinflammatory, insulin-sensitizing, and cytoprotective properties. Autophagy is a lysosome-dependent self-degradative process that mediates the degradation of damaged organelles, invading pathogens and protein aggregates, thus maintaining cellular homeostasis. Adiponectin performs different biological functions by regulating autophagy. This review attempts to elucidate the biological responses and potential mechanisms underlying adiponectin-induced autophagy, with an aim to guide the identification of new therapeutic targets of related diseases. Keywords: Adiponectin, adiponectin receptors, autophagy

Establishment of a human induced pluripotent stem cell neuronal model for identification of modulators of A53T α-synuclein levels and aggregation

Inhibiting formation or promoting degradation of α-synuclein aggregates are among the therapeutical approaches under investigation as disease-modifying treatment strategies for Parkinson’s disease. To support these developments, several in vitro models based on seeded α-synuclein aggregation have been established in immortalized cell lines and murine primary neurons. Here, we report on a humanized model with a reproducibility and throughput that enables its use in supporting target identification and validation in pharmacological research. A human induced pluripotent stem cell (iPSC) line was genetically modified to express HA-tagged α-synuclein with the point mutation in position 53 from Alanine to Threonine (A53T) under an inducible system and differentiated into cortical neurons expressing neuronal markers and exhibiting spontaneous activity. Intracellular α-synuclein aggregation was triggered by exposure to exogenous added fibrillated recombinant wild-type human α-synuclein fibrils91 and demonstrated by several endpoints; the formation of Triton-insoluble SDS-soluble α-synuclein, biochemically in a fluorescence resonance energy transfer based aggregation assay and by immunocytochemistry of phosphorylated α-synuclein positive puncta. We demonstrate the feasibility of upscaling the iPSC neuron production for drug discovery and that the model has a suitable dynamic range allowing for both detection of increased and decreased α-synuclein aggregation. Moreover, gene modulation is feasible using siRNAs, making the model suitable for genetic screening for modulators of α-synuclein aggregation. Data on effects of USP8, USP13 and USP9X knockdown on α-synuclein expression and aggregation contradicts published data from immortalized cell lines and murine systems. This highlight the importance of including humanized neuronal models in the confirmation of biological mechanisms in specific variations of Parkinson’s disease.

HYPK coordinates degradation of polyneddylated proteins by autophagy

ABSTRACT Selective degradation of protein aggregates by macroautophagy/autophagy is an essential homeostatic process of safeguarding cells from the effects of proteotoxicity. Among the ubiquitin-like proteins, NEDD8 conjugation to misfolded proteins is prominent in stress-induced protein aggregates, albeit the function of neddylation in autophagy is unclear. Here, we report that polyneddylation functions as a post-translational modification for autophagic degradation of proteotoxic-stress induced protein aggregates. We also show that HYPK functions as an autophagy receptor in the polyneddylation-dependent aggrephagy. The scaffolding function of HYPK is facilitated by its C-terminal ubiquitin-associated domain and N-terminal tyrosine-type LC3-interacting region which bind to NEDD8 and LC3 respectively. Both NEDD8 and HYPK are positive modulators of basal and proteotoxicity-induced autophagy, leading to protection of cells from protein aggregates, such as aggregates of mutant HTT exon 1. Thus, we propose an indispensable and additive role of neddylation and HYPK in clearance of protein aggregates by autophagy, resulting in cytoprotective effect during proteotoxic stress. Abbreviations: ATG5, autophagy related 5; ATG12, autophagy related 12; ATG14, autophagy related 14; BECN1, beclin 1; CBL, casitas B-lineage lymphoma; CBLB, Cbl proto-oncogene B; GABARAP, GABA type A receptor-associated protein; GABARAPL1, GABA type A receptor associated protein like 1; GABARAPL2, GABA type A receptor associated protein like 2; GFP, green fluorescent protein; HTT, huntingtin; HTT97Q exon 1, huntingtin 97-glutamine exon 1; HUWE1, HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1; HYPK, huntingtin interacting protein K; IgG, immunoglobulin G; IMR-32, Institute for Medical Research-32; KD, knockdown; Kd, dissociation constant; LAMP1, lysosomal associated membrane protein 1; LIR, LC3 interacting region; MAP1LC3/LC3, microtubule associated protein 1 light chain 3; MAP1LC3A/LC3A, microtubule associated protein 1 light chain 3 alpha; MAP1LC3B/LC3B, microtubule associated protein 1 light chain 3 beta; MARK1, microtubule affinity regulating kinase 1; MARK2, microtubule affinity regulating kinase 2; MARK3, microtubule affinity regulating kinase 3; MARK4, microtubule affinity regulating kinase 4; MCF7, Michigan Cancer Foundation-7; MTOR, mechanistic target of rapamycin kinase; NAE1, NEDD8 activating enzyme E1 subunit 1; NBR1, NBR1 autophagy cargo receptor; NEDD8, NEDD8 ubiquitin like modifier; Ni-NTA, nickel-nitrilotriacetic acid; NUB1, negative regulator of ubiquitin like proteins 1; PIK3C3, phosphatidylinositol 3-kinase catalytic subunit type 3; PolyQ, poly-glutamine; PSMD8, proteasome 26S subunit, non-ATPase 8; RAD23A, RAD23 homolog A, nucleotide excision repair protein; RAD23B, RAD23 homolog B, nucleotide excision repair protein; RFP, red fluorescent protein; RPS27A, ribosomal protein S27a; RSC1A1, regulator of solute carriers 1; SNCA, synuclein alpha; SIK1, salt inducible kinase 1; siRNA, small interfering ribonucleic acid; SOD1, superoxide dismutase 1; SPR, surface plasmon resonance; SQSTM1, sequestosome 1; SUMO1, small ubiquitin like modifier 1; TAX1BP1, Tax1 binding protein 1; TDRD3, tudor domain containing 3; TNRC6C, trinucleotide repeat containing adaptor 6C; TOLLIP, toll interacting protein; TUBA, tubulin alpha; TUBB, tubulin beta class I; UBA, ubiquitin-associated; UBA1, ubiquitin like modifier activating enzyme 1; UBA5, ubiquitin like modifier activating enzyme 5; UBAC1, UBA domain containing 1; UBAC2, UBA domain containing 2; UBAP1, ubiquitin associated protein 1; UBAP2, ubiquitin associated protein 2; UBASH3B, ubiquitin associated and SH3 domain containing B; UBD/FAT10, ubiquitin D; UBE2K, ubiquitin conjugating enzyme E2 K; UBLs, ubiquitin-like proteins; UBL7, ubiquitin like 7; UBQLN1, ubiquilin 1; UBQLN2, ubiquilin 2; UBQLN3, ubiquilin 3; UBQLN4, ubiquilin 4; UBXN1, UBX domain protein 1; ULK1, unc-51 like autophagy activating kinase 1; URM1, ubiquitin related modifier 1; USP5, ubiquitin specific peptidase 5; USP13, ubiquitin specific peptidase 13; VPS13D, vacuolar protein sorting 13 homolog D

Macroautophagy and Mitophagy in Neurodegenerative Disorders: Focus on Therapeutic Interventions

Macroautophagy, a quality control mechanism, is an evolutionarily conserved pathway of lysosomal degradation of protein aggregates, pathogens, and damaged organelles. As part of its vital homeostatic role, macroautophagy deregulation is associated with various human disorders, including neurodegenerative diseases. There are several lines of evidence that associate protein misfolding and mitochondrial dysfunction in the etiology of Alzheimer’s, Parkinson’s, and Huntington’s diseases. Macroautophagy has been implicated in the degradation of different protein aggregates such as Aβ, tau, alpha-synuclein (α-syn), and mutant huntingtin (mHtt) and in the clearance of dysfunctional mitochondria. Taking these into consideration, targeting autophagy might represent an effective therapeutic strategy to eliminate protein aggregates and to improve mitochondrial function in these disorders. The present review describes our current understanding on the role of macroautophagy in neurodegenerative disorders and focuses on possible strategies for its therapeutic modulation.

ALSTaR Cells - Novel Stem-cell-based Therapy for Amyotrophic Lateral Sclerosis: A Research Protocol

Introduction: Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that results in the loss of motor neurons leading to limb paralysis and eventual death. Stem cell transplantation can be used to replenish the atrophied motor neurons and slow the progression of the disease, while the use of biomaterials, genetic engineering, and nanoparticles can reduce the hostility of the microenvironment. Thus, we propose a novel combinatorial therapeutic approach termed Amyotrophic Lateral Sclerosis Therapeutic and Regenerative (ALSTaR) cell treatment. Methods: This unified strategy will employ miRNA-124 and chitosan polyplex biomaterial to subsequently enhance engraftment of neural progenitor cells (NPCs), which will be engineered to overexpress an autophagy-regulatory gene, TFEB, and secrete an autophagy-inducing drug, trehalose. We will bioengineer an organoid model of the ventral column of the spinal cord which will be used for extensive in vitro characterization of ALSTaR cells through single-slice electrophysiology and immunocytochemistry, followed by in vivo work. Using the SOD1G93A mutant mouse model, weekly behavioural assessments of motor recovery will be conducted until the humane endpoint; thereafter extensive immunohistochemical and protein quantification analyses will be performed to determine treatment efficacy. Results: ALSTaR cell treatment should result in motor functional recovery and lifespan elongation through several cellular and molecular mechanisms, including decreased neuroinflammation, upregulation of autophagy, degradation of protein aggregates, enhancement of transplanted cell integration, and regeneration of axons. Discussion: In vitro characterization of ALSTaR cells in bioengineered spinal cord organoids will reveal stable electrophysiological recordings of motor neurons, higher levels of neuronal differentiation markers, and lower levels of inflammation markers in the ALSTaR group compared to the control group or the groups treated with just the biomaterial or just the NPCs, suggesting neuronal recovery. Behavioural assessments in the ALS mouse model will reveal increased motor coordination, neuromuscular strength, and motor activity in the ALSTaR group compared to other groups, suggesting motor functional recovery. In vivo characteriz ation of ALSTaR cells in the ALS mouse model will suggest enhanced stem cell integration and recovery of cellular and molecular processes. Conclusion: With currently no effective treatment for ALS, this novel combinatorial treatment strategy could improve the health-related quality of life of patients suffering from this debilitating disease.

Rab7 reduces α-synuclein toxicity in rats and primary neurons

During the pathogenesis of Parkinson's disease (PD), aggregation of alpha-synuclein (αSyn) induces a vicious cycle of cellular impairments that lead to neurodegeneration. Consequently, removing toxic αSyn aggregates constitutes a plausible strategy against PD. In this work, we tested whether stimulating the autolysosomal degradation of αSyn aggregates through the Ras-related in brain 7 (Rab7) pathway can reverse αSyn-induced cellular impairment and prevent neurodegeneration in vivo. The disease-related A53T mutant of αSyn was expressed in primary neurons and in dopaminergic neurons of the rat brain simultaneously with wild type (WT) Rab7 or the T22N mutant as negative control. The cellular integrity was quantified by morphological and biochemical analyses. In primary neurons, WT Rab7 rescued the αSyn-induced loss of neurons and neurites. Furthermore, Rab7 decreased the amount of reactive oxygen species and the amount of Triton X-100 insoluble αSyn. In rat brain, WT Rab7 reduced αSyn-induced loss of dopaminergic axon terminals in the striatum and the loss of dopaminergic dendrites in the substantia nigra pars reticulata. Further, WT Rab7 lowered αSyn pathology as quantified by phosphorylated αSyn staining. Finally, WT Rab7 attenuated αSyn-induced DNA damage in primary neurons and rat brain. In brief, Rab7 reduced αSyn-induced pathology, ameliorated αSyn-induced neuronal degeneration, oxidative stress and DNA damage. These findings indicate that Rab7 is able to disrupt the vicious cycle of cellular impairment, αSyn pathology and neurodegeneration present in PD. Stimulation of Rab7 and the autolysosomal degradation pathway could therefore constitute a beneficial strategy for PD.

FUS-induced neurotoxicity is prevented by inhibiting GSK-3β in a Drosophila model of amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis (ALS)-linked mutations in fused in sarcoma (FUS) lead to the formation of cytoplasmic aggregates in neurons. They are believed to play a critical role in the pathogenesis of FUS-associated ALS. Therefore, the clearance and degradation of cytoplasmic FUS aggregates in neurons may be considered a therapeutic strategy for ALS. However, the molecular pathogenic mechanisms behind FUS-associated ALS remain poorly understood. Here, we report GSK-3β as a potential modulator of FUS-induced toxicity. We demonstrated that RNAi-mediated knockdown of Drosophila ortholog Shaggy in FUS-expressing flies suppresses defective phenotypes, including retinal degeneration, motor defects, motor neuron degeneration and mitochondrial dysfunction. Furthermore, we found that cytoplasmic FUS aggregates were significantly reduced by Shaggy knockdown. In addition, we found that the levels of FUS proteins were significantly reduced by co-overexpression of Slimb, a F-box protein, in FUS-expressing flies, indicating that Slimb is critical for the suppressive effect of Shaggy/GSK-3β inhibition on FUS-induced toxicity in Drosophila. These findings revealed a novel mechanism of neuronal protective effect through SCFSlimb-mediated FUS degradation via GSK-3β inhibition, and provided in vivo evidence of the potential for modulating FUS-induced ALS progression using GSK-3β inhibitors.

Direct observation of aggregate-triggered selective autophagy in human cells.

ABSTRACTDegradation of aggregates by selective autophagy is important as damaged proteins may impose a threat to cellular homeostasis. Although the core components of the autophagy machinery are well characterized, the spatiotemporal regulation of many selective autophagy processes, including aggrephagy, remains largely unexplored. Furthermore, because most live-cell imaging studies have so far focused on starvation-induced autophagy, little is known about the dynamics of aggrephagy. Here, we describe the development and application of the mKeima-PIM assay, which enables live-cell observation of autophagic turnover and degradation of inducible protein aggregates in conjunction with key autophagy players. This allowed us to quantify the relative timing and duration of different steps of aggrephagy in human cells and revealed the short-lived nature of the autophagosome. The assay furthermore showed the spatial distribution of omegasome formation, highlighting that autophagy initiation is directly instructed by the cargo. Moreover, we found that nascent autophagosomes mostly remain immobile until acidification occurs. Thus, our assay provides new insights into the spatiotemporal regulation and dynamics of aggrephagy. This article has an associated First Person interview with the first author of the paper.

Intranasal delivery of mesenchymal stem cells-derived extracellular vesicles for the treatment of neurological diseases.

Neurological disorders are diseases of the central nervous system (CNS), characterized by a progressive degeneration of cells and deficiencies in neural functions. Mesenchymal stem cells (MSCs) are a promising therapy for diseases and disorders of the CNS. Increasing evidence suggests that their beneficial abilities can be attributed to their paracrine secretion of extracellular vesicles (EVs). Administration of EVs that contain a mixture of proteins, lipids, and nucleic acids, resembling the secretome of MSCs, has been shown to mimic most of the effects of the parental cells. Moreover, the small size and safety profile of EVs provide a number of advantages over cell transplantation. Intranasal (IN) administration of EVs has been established as an effective and reliable way to bypass the blood-brain barrier and deliver drugs to the CNS. In addition to pharmacological drugs, EVs can be loaded with a diverse range of cargo designed to modulate gene expression and protein functions in recipient cells, and lead to immunomodulation, neurogenesis, neuroprotection, and degradation of protein aggregates. In this review, we will explore the proposed physiological pathways by which EVs migrate through the nasal route to the CNS where they can actively target a region of injury or inflammation and exert their therapeutic effects. We will summarize the functional outcomes observed in animal models of neurological diseases following IN treatment with MSC-derived EVs. We will also examine key mechanisms that have been suggested to mediate the beneficial effects of EV-based therapy.

Oligomerization of Selective Autophagy Receptors for the Targeting and Degradation of Protein Aggregates.

The selective targeting and disposal of solid protein aggregates are essential for cells to maintain protein homoeostasis. Autophagy receptors including p62, NBR1, Cue5/TOLLIP (CUET), and Tax1-binding protein 1 (TAX1BP1) proteins function in selective autophagy by targeting ubiquitinated aggregates through ubiquitin-binding domains. Here, we summarize previous beliefs and recent findings on selective receptors in aggregate autophagy. Since there are many reviews on selective autophagy receptors, we focus on their oligomerization, which enables receptors to function as pathway determinants and promotes phase separation.

Role of Autoantibodies in Neurodegenerative Dementia: An Emerging Association

Objective: In the background of an emerging role for immune dysregulation in neurodegenerative dementias, this study aimed to investigate the relationship between systemic autoimmunity and dementia. The objective was to study the frequency and profile of disease-specific autoantibodies in Alzheimer’s dementia (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB). Methods: Immunological testing was performed in a large cohort of neurodegenerative dementia diagnosed based on standard clinical and imaging criteria. Patients were evaluated for the presence of autoantibodies specific for systemic autoimmune diseases that included anti-extractable nuclear antibody profile, rheumatoid factor antibody (RA), perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA), and cytoplasmic anti-neutrophil cytoplasmic antibody (c-ANCA) in serum. Results: Of 174 patients with degenerative dementia (FTD = 114, AD = 53, and DLB = 7) evaluated with immunological testing, 18.9% (n = 33) were seropositive for autoantibodies. The common antibodies detected were anti-Scl-70 (25%), anti-Ro-52 (18.7%), anti-nRNP-Sm (12.5%), and anti-CENP-B (9.3%). There were no significant systemic complaints in the majority of patients. A wider range of antibodies were positive in FTD compared to AD and DLB. While no difference was observed in the mean age, sex, or duration of illness between seropositive and negative patients, family history of dementia was more frequent among seronegative patients. Conclusion: Our findings indicate an emerging role for immune dysregulation in patients with classical neurodegenerative dementias, especially those with FTD. These autoantibodies could play a role in immune degradation of protein aggregates that characterize neurodegeneration. Study findings emphasize the need to explore the complex relationship between systemic autoimmunity and neurodegenerative dementia.